Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Further Reading

Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company.

From Optibrium Ltd. 23 Nov 2022

Providing structural understanding of the influenza virus

Providing structural understanding of the influenza virus

The structure of the influenza replication machinery and how it interacts with cellular proteins have been solved by a team of Oxford University scientists using a variety of techniques at Diamond Light Source.

8 Nov 2022

New bioprinting platform to replicate tumors in 3D spheroids

New bioprinting platform to replicate tumors in 3D spheroids

Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumors in 3D models.

3 Nov 2022

Drug discovery method facilitates promising treatment approaches for metabolic diseases

Drug discovery method facilitates promising treatment approaches for metabolic diseases

The body’s chemical processes known as “metabolism” produce the raw materials needed for development and general health.

17 Oct 2022

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

From PhoreMost 6 Sep 2022

Detecting multiple food poisoning bacteria based on color differences in scattered light from metals

Detecting multiple food poisoning bacteria based on color differences in scattered light from metals

Osaka Metropolitan University scientists have developed a simple, rapid method to simultaneously identify multiple food poisoning bacteria, based on color differences in the scattered light by nanometer-scaled organic metal nanohybrid structures (NHs) that bind via antibodies to those bacteria.

30 Aug 2022

Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market

Inventia Life Science Accelerates Growth with AU$35 million Series B Led by Blackbird Ventures, Launching 3D Cell Culture Platform into US Market

Company aims to democratise access to affordable biomedical research especially in cancer research and new drug development through its novel 3D cell culture platform

From Inventia Life Science 16 Aug 2022

Australian company accelerating the speed of drug discovery wins prestigious Eureka prize

Australian company accelerating the speed of drug discovery wins prestigious Eureka prize

Inventia Life Science announced that its RASTRUM™ 3D cell culture platform has won the ANSTO Eureka Prize for Innovative Use of Technology at the 2021 Australian Museum Eureka Prizes.

From Inventia Life Science 16 Aug 2022

Inventia Life Science partners with Xylyx Bio to develop tissue-specific, digitally-printed bioinks for drug discovery

Inventia Life Science partners with Xylyx Bio to develop tissue-specific, digitally-printed bioinks for drug discovery

Inventia Life Science and Xylyx Bio today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.

From Inventia Life Science 16 Aug 2022

RASTRUM™ - the 3D Printer of Living Cells, Honored in Annual Awards by Leading Business Magazine

RASTRUM™ - the 3D Printer of Living Cells, Honored in Annual Awards by Leading Business Magazine

RASTRUM™ has taken out the top prize in the Experimental category. RASTRUM™ prints human cells into living tissue models to supercharge research into cancer and other diseases using revolutionary drop-on-demand technology.

From Inventia Life Science 16 Aug 2022

Inventia Life Science Announces Partnership with PhenoVista Biosciences to Accelerate Preclinical Research with 3D Cell Models

Inventia Life Science Announces Partnership with PhenoVista Biosciences to Accelerate Preclinical Research with 3D Cell Models

Inventia Life Science, a leader in automated generation of complex 3D cell models, and PhenoVista Biosciences, a top provider of custom imaging-based phenotypic assay services, have entered into a partnership to deliver high-content cell-based assay services for drug discovery.

From Inventia Life Science 16 Aug 2022

Sample management innovation on tour

Sample management innovation on tour

Sample management specialists - Ziath announce they will be exhibiting their latest DP5 range scanners and readers at most major laboratory and automation events across Europe over the next few months.

From Ziath Ltd 11 Aug 2022

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services.

From CN Bio Innovations Limited 19 Jul 2022

New technique enables researchers to pinpoint protein–drug interaction

New technique enables researchers to pinpoint protein–drug interaction

The discovery and development of new drugs may be facilitated by the use of a novel method that can analyze the interactions of drug molecules with proteins in tissue samples. In cooperation with the major biopharmaceutical company AstraZeneca, University of Birmingham researchers created the method.

15 Jul 2022

Challenges in Drug Discovery; Where are we now, and where are we going?

Challenges in Drug Discovery; Where are we now, and where are we going?

As part of our SLAS Europe 2022 coverage, we speak to Steve Rees, Vice-President of Discovery Biology at AstraZeneca, about the challenges currently faced by the drug discovery sector.

From Society for Laboratory Automation and Screening (SLAS) 8 Jul 2022

How Important is the European Ecosystem to Life Sciences Research?

How Important is the European Ecosystem to Life Sciences Research?

As part of our SLAS Europe 2022 coverage, we speak to Jan Lichtenberg, vice president of SLAS, about the role Europe plays within life sciences research.

From Society for Laboratory Automation and Screening (SLAS) 7 Jul 2022

How can High-Content Screening accelerate Drug Discovery?

How can High-Content Screening accelerate Drug Discovery?

As part of our SLAS Europe 2022 coverage, we speak to Professor Jeremy Simpson from the University College Dublin about the role high-content screening can play in accelerating drug discovery.

From Society for Laboratory Automation and Screening (SLAS) 6 Jul 2022

New biomedical research tool may help advance molecular diagnostics and drug discovery

New biomedical research tool may help advance molecular diagnostics and drug discovery

A new biomedical research tool that enables scientists to measure hundreds of functional proteins in a single cell could offer new insights into cell machinery.

30 Jun 2022

Integrating Science, Software, and Data to Accelerate Antibody Discovery

Integrating Science, Software, and Data to Accelerate Antibody Discovery

As part of our SLAS Europe 2022 coverage, we speak to Andrew LeBeau, Associate Vice President for Product Integrations at Dotmatics, about the importance of managing data within the life sciences and Dotmatic's Biology Solution for Antibody Discovery.

From Society for Laboratory Automation and Screening (SLAS) 16 Jun 2022

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.

From Orbit Discovery 14 Jun 2022

Previous
1
2
3
4
5
6
7
...
14
Next